Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02351856 · ClinicalTrials.gov registry record · Phase 2
A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
A Phase 2 study of LMNA-Related Dilated Cardiomyopathy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 4
- Study locations
NCT02351856: Completed Phase 2 study of LMNA-Related Dilated Cardiomyopathy, sponsored by Pfizer.
NCT02351856 is a Phase 2 study of LMNA-Related Dilated Cardiomyopathy that has completed, run by Pfizer. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02351856, a Phase 2 study of LMNA-Related Dilated Cardiomyopathy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between baseline up to 30 days after last dos
Conditions Studied
Interventions
- DRUG ARRY-371797, p38 inhibitor, oral
Study Locations (4)
Colorado
- University of Colorado Hospital - Aurora
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Brigham & Women's Hospital - Boston
Wisconsin
- Meriter Wisconsin Heart - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-02-02 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 2 |
What the finished NCT02351856 record still lists
NCT02351856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with LMNA-Related Dilated Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which ARRY-371797, p38 inhibitor, oral is the first listed.
NCT02351856 reports a single indexed study location in Colorado, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02351856 about?
NCT02351856 is a clinical study titled "A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy". This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion...
What is the current status of trial NCT02351856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2015-02-02. Estimated completion is 2020-12-21.
What conditions does trial NCT02351856 study?
This clinical trial studies the following conditions: LMNA-Related Dilated Cardiomyopathy.
What interventions are being tested in trial NCT02351856?
The interventions under investigation include: ARRY-371797, p38 inhibitor, oral (DRUG).
Who is sponsoring clinical trial NCT02351856?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02351856 being conducted?
This trial has 4 study locations across Colorado, Maryland, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02351856's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI